ClinicalTrials.gg
CompletedNCT07115277Updated Nov 6, 2026

Diagnostic Efficacy and Safety of Flotufolastat F-18 Injection in Subjects With Biochemical Recurrence of Prostate Cancer

An interventional study of Flotufolastat F-18 Injection in Prostate Cancer, sponsored by Sinotau Pharmaceutical Group. Completed at 1 site in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Sinotau Pharmaceutical Group · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Feb 2025, registered Aug 2025).
Updated Nov 6, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
121
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing flotufolastat F 18 in Prostatic Neoplasms — 6 open to participants now, 7 under way, 2 of them phase 3. flotufolastat F 18 · Prostatic Neoplasms.

Enrollment
3rd of 15
121 · median 70
Started
2025
with 6 others
No phase
2 of 15
1 open now
Registered
12th of 15
by date
Lead sponsor
2 of 15
Sinotau Pharmaceutical Group

Among the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms, this one is the 3rd largest by enrollment, is one of 7 that started in 2025, is one of 2 with no phase, and was the 12th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About flotufolastat F 18

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing flotufolastat F 18 in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the diagnostic performance and safety of Flotufolastat F-18 injection PET imaging in prostate cancer subjects with biochemical recurrence following prior treatment. The main question it aims to answer is:

  • What is the correct detection rate of Flotufolastat F 18 injection PET visual reading results compared to the truth standard?

Participants will:

  • Receive Flotufolastat F-18 injection
  • Undergo PET/CT scanning
03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Fully understand the study and voluntarily sign the form. 2. Male, aged ≥18 years. 3. Has previously received one or more of the following treatments:

  1. Radical prostatectomy (RP);
  2. RP with radiotherapy (RT);
  3. RP with adjuvant androgen deprivation therapy (ADT);
  4. Radical RT or focal gland therapy (e.g., brachytherapy, high-intensity focused ultrasound [HIFU]).

    4. Clinically suspected BCR, serum PSA levels should meet at least one of the followings:

    1. After RP with or without adjuvant or salvage therapy: PSA≥ 0.2 ng/mL, and subsequent confirmation that PSA ≥ 0.2 ng/mL.
    2. After RT as primary treatment: PSA increased at least 2 ng/mL compaire to the nadir.
    3. After focal gland therapy as primary treatment: PSA increased at least 2 ng/mL compaire to the nadir.

    5. If positive lesions are detected on the XTR020 PET imaging or conventional imaging, the subject is willing to receive histopathological confirmation or the sequqnce of conventional imaging confirmation.

    6. Male subjects with must use effective during the study period and 6 months after the study completed; their partners should agree to use contraception during the study period and 6 months after the study completed , too.

Exclusion criteria

Exclusion Criteria:

  1. Planned to receive an X-ray contrast agent or other radioactive imaging agent within 24 hours before XTR020 PET imaging.
  2. Participation in an interventional clinical trial involving a new drug or treatment within 30 days or 5 biological half-lives of the drug prior to XTR020 PET imaging (whichever is longer).
  3. Known allergy to the active ingredient or any of XTR020.
  4. Claustrophobia or inability to tolerate imaging examinations for any other reason.
  5. Poor compliance or deemed unsuitable for participation in this study by the investigator.
  6. Any condition that, in the opinion of the investigator, may interfere with data collection or prevent the study requirements.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    All prostate cancer subjects will undergo PET imaging using Flotufolastat F-18 Injection

    Drug: Flotufolastat F-18 Injection

Interventions

  • All patients will receive one injection of Flotufolastat F-18 Injection, a PET radiopharmaceutical selective for PSMA. For the injection, subjects will receive a target dose of 8 mCi (296 MBq) ± 20% IV as a bolus injection. Flotufolastat F-18 Injection will be followed by a 10 ml saline flush.

06

What researchers measure

Primary outcomes

  1. To evaluate the diagnostic performance of Flotufolastat F-18 Injection PET imaging in Chinese prostate cancer subjects with biochemical recurrence (BCR)

    Correct Detection Rate (CDR) at the individual level of Flotufolastat F-18 Injection PET imaging in prostate cancer subjects with BCR

    Time frame: 90 days

Secondary outcomes

  1. To evaluate other diagnostic performance parameters of Flotufolastat F-18 Injection PET imaging in Chinese prostate cancer subjects with BCR

    Positive predictive value (PPV) of Flotufolastat F-18 Injection PET imaging at the individual level in prostate cancer subjects with BCR. PPV and CDR of Flotufolastat F-18 Injection PET imaging in the prostate bed, pelvic lymph nodes, and three other regions in Chinese prostate cancer subjects with BCR.

    Time frame: 90 days

  2. To evaluate the diagnostic performance of Flotufolastat F-18 Injection PET imaging in different subgroups of Chinese prostate cancer subjects with BCR

    Individual-level PPV and CDR of Flotufolastat F-18 Injection PET imaging in subjects whose baseline conventional imaging is negative. Individual-level PPV and CDR of Flotufolastat F-18 Injection PET imaging at different PSA levels.

    Time frame: 90 days

  3. To evaluate inter-reader and intra-reader interpretative consistency among independent blinded readers.

    Kappa values for inter-reader and intra-reader agreement in the interpretation of the same Flotufolastat F-18 Injection PET imaging by different independent blinded readers and by the same reader at different times.

    Time frame: 90 days

  4. To evaluate the safety of Flotufolastat F-18 Injection .

    The types, severity, frequency, and outcomes of adverse events/serious adverse events reported during the study period.

    Time frame: 3 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Dec 2025, 9 months.

Of 57 industry-sponsored interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 72. This study's 9 months is below that.

Counting every sponsor, half of 1,157 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Mar 2025 → Feb 2025, primary completion Dec 2026 → Dec 2025 and completion Dec 2026 → Jan 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 11, 2025
StartActual
Feb 19, 2025was Mar 2025
Primary completionActual
Dec 18, 2025was Dec 2026
CompletionActual
Jan 27, 2026was Dec 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 6, 2026
Start date
Mar 14, 2025→Feb 19, 2025
Nov 6, 2026
Primary completion
Dec 31, 2026→Dec 18, 2025 (actual)
Nov 6, 2026
Study completion
Dec 31, 2026→Jan 27, 2026 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Completed
    Start date Mar 14, 2025→Feb 19, 2025
    Primary completion Dec 31, 2026→Dec 18, 2025 (now actual)
    Study completion Dec 31, 2026→Jan 27, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07115277
Lead sponsor
Sinotau Pharmaceutical Group
Responsible party
Sponsor
First posted
Aug 11, 2025
Start date
Feb 19, 2025
Primary completion
Dec 18, 2025
Completion
Jan 27, 2026
Last update
Nov 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flotufolastat F 18

Start the discussion